Clinical Trials and Research
Research is how CMT moves toward treatments, and patients are at the center of it. Nothing gets approved without people who volunteer first. More CMT trials are running now than at any point in CMT history, and several go after the genetic causes, not just the symptoms. Not every trial will suit you, and some need a subtype you do not have, but knowing what is out there puts you in a stronger position with your neurologist. This page explains how to find trials, what taking part involves, and why your subtype is the key to eligibility.
At a glance
- Clinical trials test whether a new treatment is safe and whether it works.
- Trials are organized by subtype, so confirming yours is the first step to eligibility; see CMT Genie.
- Not all research is a drug trial. Natural history studies track how CMT changes over time and are just as important.
- Joining the GRIN Registry is the simplest way to be found for studies you may qualify for.
- Taking part is voluntary at every step, and informed consent means you always know what is involved.
- Your care team and a Center of Excellence can help you weigh whether a trial is right for you.
Why patients drive the research
A treatment cannot be approved until it is tested in people, and that testing depends on patients who choose to take part. In a field like CMT, where each subtype is its own puzzle, the willingness of patients to be counted and to enroll is what makes trials possible in the first place. Research is not something that happens to the community. It is something the community builds.
The kinds of studies
Interventional trials test a specific treatment, and they move through phases: early phases focus on safety in a small group, and later phases test whether the treatment works in more people. Natural history studies do not test a treatment at all. They carefully track how a subtype changes over time, which is essential groundwork, because you cannot measure whether a treatment helps without first knowing what usually happens without it.
Both matter. Many people begin by contributing to a registry or a natural history study long before an interventional trial for their subtype exists.
Why your subtype decides eligibility
Because a therapy aimed at one gene may do nothing for another, trials recruit by subtype. That makes a confirmed genetic diagnosis the practical key to taking part. If you have not confirmed your subtype yet, CMT Genie, HNF's patient-initiated genetic-testing program, is the place to start.
How to find trials you may qualify for
The simplest on-ramp is the GRIN Registry. When you enroll, your consented information helps researchers identify studies you may be eligible for and reach you when one opens. Your neurologist and a Center of Excellence are also well placed to tell you what is recruiting for your subtype. HNF's research pages describe the studies and infrastructure the Foundation supports.
What taking part involves
Every trial begins with informed consent, a clear explanation of the study's purpose, what you would do, the possible benefits and risks, and your right to leave at any time without affecting your regular care. Participation is always voluntary. A trial may involve extra visits, tests, or a treatment that is still being studied, so it is worth talking it through with your care team and the people close to you before deciding. Choosing not to take part is always a valid choice, and joining the registry keeps the door open for the future.
Start with your subtype
The most useful first step in living well with CMT is confirming your subtype. From there, the right care and research opportunities fall into place.